95
Participants
Start Date
May 26, 2021
Primary Completion Date
April 30, 2026
Study Completion Date
January 31, 2027
APG-115
Dose escalation of APG-115 in combination with label dose of toripalimab, four dose levels of APG-115 will be tested: 50, 100, 150, and 200mg. APG-115 will be administrated orally every other day (QOD) for consecutive 2 weeks (ie. dosed at Day 1, 3, 5, 7, 9, 11, and 13), with one week dosing off as 3 weeks a cycle.
Toripalimab
Toripalimab is administrated following CDE approved label dose, i.e.: 240 mg intravenous infusion at Day 1 of every 3 weeks as a cycle.
NOT_YET_RECRUITING
Cancer Hospital of The University of Chinese Academy of Sciences, Hangzhou
RECRUITING
Sun Yat-sen University Cancer Center, Guangzhou
RECRUITING
Shanghai East Hospital (East Hospital affiliated to Tongji University), Shanghai
Lead Sponsor
Suzhou Yasheng Pharmaceutical Co., Ltd.
INDUSTRY
Ascentage Pharma Group Inc.
INDUSTRY